Nektar Therapeutics (NKTR)
| Market Cap | 2.97B |
| Revenue (ttm) | 163.32M |
| Net Income (ttm) | -440.68M |
| Shares Out | 179.09M |
| EPS (ttm) | -2.48 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $16.56 |
| Previous Close | $16.66 |
| Change ($) | -0.10 |
| Change (%) | -0.60% |
| Day's Open | 16.53 |
| Day's Range | 16.41 - 16.71 |
| Day's Volume | 681,267 |
| 52-Week Range | 14.47 - 24.79 |
SAN FRANCISCO, Jan. 6, 2021 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 39th Annual J.P. Mo...
We believe that Nektar Therapeutics stock, a biopharmaceutical company focused on discovering and developing medicines in areas that include cancer, autoimmune disease, and chronic pain, is a ...
These are the stocks posting the largest moves after hours on Tuesday.
SAN FRANCISCO, Jan. 5, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that it has appointed Brian Kotzin, MD as Interim Chief Medical Officer, Head of Development effe...
Investors need to pay close attention to Nektar Therapeutics (NKTR) stock based on the movements in the options market lately.
Nektar (NKTR) doses the first patient in a phase I/II study on NKTR-255 in combination with Erbitux for treating head and neck squamous cell carcinoma or colorectal cancer. Shares up.
SAN FRANCISCO, Dec. 7, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced two nonclinical data presentations for NKTR-255, its IL-15 pathway agonist, at the 62nd American ...
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock?
Nectar, a global leader in polymer chemistry-based drug discovery, has no major near-term catalysts, a vast pipeline and numerous big pharma collaborations. It recently published a set of 3 tr...
SAN FRANCISCO, Nov. 11, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced four data presentations for its I-O pipeline from three separate clinical-stage investigational ...
Nektar (NKTR) reports encouraging third-quarter 2020 results. Enrollment in clinical studies back on track.
Nektar Therapeutics (NKTR) CEO Howard Robin on Q3 2020 Results - Earnings Call Transcript
Nektar (NKTR) delivered earnings and revenue surprises of 23.75% and 39.34%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
SAN FRANCISCO, Nov. 5, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today reported financial results for the third quarter ended September 30, 2020. Cash and investments in marketab...
SAN FRANCISCO, Nov. 4, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced the presentation of additional clinical data from the Phase 1b study evaluating multiple ascending doses...
SAN FRANCISCO, Oct. 29, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that it will webcast an analyst and investor conference call at ACR 2020 with company management...
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN FRANCISCO, Oct. 28, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2020 on Thursday, November 5, 2020, after the close of...
SAN FRANCISCO, Oct. 27, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that it has received FDA clearance for an Investigational New Drug (IND) application for its inv...
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock?
Nektar is largely marking time ahead of some "medium impact" trial updates in November and game-changing updates in 2021 for the melanoma and bladder cancer programs.
Nektar (NKTR) reports encouraging second-quarter 2020 results. The company continues to progress with its pipeline candidates.
Nektar Therapeutics (NKTR) CEO Howard Robin on Q2 2020 Results - Earnings Call Transcript
Nektar (NKTR) delivered earnings and revenue surprises of 34.78% and 113.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
SAN FRANCISCO, Aug. 6, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2020.
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN FRANCISCO, July 28, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2020 on Thursday, August 6, 2020, after the close of ...
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock?
SAN FRANCISCO, June 4, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced the presentation of results from the Phase 1b study evaluating multiple ascending doses of NKTR-35...
Lee Ainslie (Trades, Portfolio)’s Maverick Capital bought shares of the following stocks in both the fourth quarter of 2019 and the first quarter of 2020.
SAN FRANCISCO, May 22, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of Phase 1 clinical data for its lead immuno-oncology candidate, bempegaldesleuki...
Nektar Seeing Modest Covid-19 Delays Ahead Of Key Trial Data
Nektar (NKTR) reports encouraging first-quarter 2020 results. The company continues to progress with its pipeline candidates.
Nektar Therapeutics (NKTR) CEO Howard Robin on Q1 2020 Results - Earnings Call Transcript
Nektar (NKTR) delivered earnings and revenue surprises of 34.57% and 12.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock?
Nektar Therapeutics (NKTR) CEO Howard Robin on Q4 2019 Results - Earnings Call Transcript
Nektar (NKTR) reports encouraging fourth-quarter results. The company continues to progress with its pipeline candidates.
The biotech topped Wall Street estimates, but the real focus was on its pipeline.
Nektar (NKTR) delivered earnings and revenue surprises of 7.25% and 28.57%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Nektar Therapeutics (NKTR) closed at $22.81 in the latest trading session, marking a -0.52% move from the prior day.
The only thing more important than what to buy is what not to buy. These biotech stocks are at the top of the avoid list.
Pricing concerns have resurfaced among biotech stocks this month. The recent pullback could offer a buying opportunity.
As the biotechnology group is pushing near all-time highs, this past week played host to a huge number of biotech movers.
Nektar Therapeutics (NASDAQ: NKTR) shares were crushed on Wednesday after the U.S.
In a 27-0 shutout, the advisory committee voted against approval of the company's pain drug, oxycodegol.
Nektar Therapeutics pulled its application for a pain drug called oxycodegol after a Food and Drug Administration committee rejected it — sending NKTR stock into a slide Wednesday.
The biotech is throwing in the towel on an experimental painkiller after receiving a thumbs-down from two FDA advisory committees.
About NKTR
Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. The company develops NKTR-181, a novel mu-opioid analgesic drug, which is in Phase III clinical trial for chronic low back pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I is designed to provide rap... [Read more...]
| Industry Biotechnology | IPO Date May 3, 1994 |
| CEO Howard Robin | Employees 723 |
| Stock Exchange NASDAQ | Ticker Symbol NKTR |
Analyst Forecasts
According to 15 analysts, the average rating for NKTR stock is "Buy." The 12-month stock price forecast is 30.23, which is an increase of 82.55% from the latest price.